To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.
The present study comparing the safety and efficacy of 1.25mg/0.05mL Bevacizumab injection via the intracameral route versus the intravitreal route in treating the neovascular glaucoma
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
40
A/C injection of 1.25 mg/0.05 mL bevacizumab
Vitreous injection of 1.25 mg/0.05 mL bevacizumab
Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla University
Hat Yai, Changwat Songkhla, Thailand
RECRUITINGregression of nevolascularization
Amount of nevolascular of iris and angle regression
Time frame: 2 months
IOP reduction
IOP reduction at 2-month visit compare to baseline
Time frame: 2 months
Injection complication
Hyphema, IOP spike
Time frame: 2 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.